Nurix Therapeutics Management
Management criteria checks 4/4
Nurix Therapeutics' CEO is Arthur Sands, appointed in Sep 2014, has a tenure of 9.58 years. total yearly compensation is $4.36M, comprised of 13.5% salary and 86.5% bonuses, including company stock and options. directly owns 0.52% of the company’s shares, worth $4.19M. The average tenure of the management team and the board of directors is 4.2 years and 3.6 years respectively.
Key information
Arthur Sands
Chief executive officer
US$4.4m
Total compensation
| CEO salary percentage | 13.5% |
| CEO tenure | 9.6yrs |
| CEO ownership | 0.5% |
| Management average tenure | 4.2yrs |
| Board average tenure | 3.6yrs |
Recent management updates
Recent updates
Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies
Apr 15Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 28% Price Boost Is Out Of Tune With Revenues
Apr 14
Improved Revenues Required Before Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Find Their Feet
Feb 20Nurix Therapeutics: Recovering Thanks To ASH, But I Think It's Priced Just Right For Now
Jan 16Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation
Dec 29Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 29% Dip In Price Shows Sentiment Is Matching Revenues
Oct 14Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher
Oct 13Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation
Sep 30Party Time: Brokers Just Made Major Increases To Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Earnings Forecasts
Apr 18We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully
Apr 15We're Keeping An Eye On Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate
Nov 28Nurix Therapeutics GAAP EPS of -$0.90 beats by $0.07, revenue of $10.79M misses by $1.29M
Oct 06Nurix Therapeutics GAAP EPS of -$1.01 misses by $0.02, revenue of $11.43M beats by $0.93M
Jul 07FDA approves expansion of Nurix Therapeutics' phase 1 trial of NX-1607 into the U.S.
Jun 30We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully
Jun 21We Think Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Drive Business Growth
Mar 07Nurix: Advancing Targeted Protein Modulation Therapies
Nov 21Companies Like Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Invest In Growth
Nov 21We're Not Worried About Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn
Jul 24Nurix Therapeutics appoints new operations chief
Jun 21Nurix Therapeutics adds Clay Siegall to its board of directors
Jun 01Here's Why We're Not At All Concerned With Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation
Apr 15CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Feb 29 2024 | n/a | n/a | -US$145m |
| Nov 30 2023 | US$4m | US$591k | -US$144m |
| Aug 31 2023 | n/a | n/a | -US$149m |
| May 31 2023 | n/a | n/a | -US$157m |
| Feb 28 2023 | n/a | n/a | -US$179m |
| Nov 30 2022 | US$9m | US$572k | -US$180m |
| Aug 31 2022 | n/a | n/a | -US$171m |
| May 31 2022 | n/a | n/a | -US$154m |
| Feb 28 2022 | n/a | n/a | -US$135m |
| Nov 30 2021 | US$5m | US$539k | -US$117m |
| Aug 31 2021 | n/a | n/a | -US$99m |
| May 31 2021 | n/a | n/a | -US$89m |
| Feb 28 2021 | n/a | n/a | -US$63m |
| Nov 30 2020 | US$17m | US$521k | -US$43m |
| Aug 31 2020 | n/a | n/a | -US$37m |
| May 31 2020 | n/a | n/a | -US$21m |
| Feb 29 2020 | n/a | n/a | -US$24m |
| Nov 30 2019 | US$1m | US$474k | -US$22m |
Compensation vs Market: Arthur's total compensation ($USD4.36M) is about average for companies of similar size in the US market ($USD3.47M).
Compensation vs Earnings: Arthur's compensation has been consistent with company performance over the past year.
CEO
Arthur Sands (61 yo)
9.6yrs
Tenure
US$4,363,120
Compensation
Dr. Arthur T. Sands, M.D., Ph D., has been the Chief Executive Officer and Director of Nurix Therapeutics, Inc. (formerly, Nurix Inc.) since September 2014 and has been its President since June 2020. Dr. S...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 9.6yrs | US$4.36m | 0.52% $ 4.2m | |
| Chief Financial Officer | 8.1yrs | US$1.61m | 0.12% $ 928.7k | |
| Chief Scientific Officer | 3.8yrs | US$1.63m | 0.061% $ 494.7k | |
| Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Senior Accounting Manager | no data | no data | no data | |
| Chief Legal Officer | 4.6yrs | US$1.65m | 0.029% $ 236.8k | |
| Chief People Officer | 1.7yrs | no data | no data | |
| Chief Business Officer | 3.8yrs | no data | no data | |
| VP & Head of Clinical Operations | 4.7yrs | no data | no data | |
| Senior VP & Head of Early Drug Discovery | 3.3yrs | no data | no data |
4.2yrs
Average Tenure
57yo
Average Age
Experienced Management: NRIX's management team is considered experienced (4.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 9.6yrs | US$4.36m | 0.52% $ 4.2m | |
| Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 4.7yrs | US$179.30k | 0% $ 0 | |
| Member of Medical Advisory Board | 1.3yrs | no data | no data | |
| Independent Director | 2.5yrs | US$225.79k | 0% $ 0 | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Independent Director | 4.8yrs | US$228.29k | 0.091% $ 734.2k | |
| Independent Chairman | 8yrs | US$202.55k | 0.056% $ 453.0k | |
| Independent Director | 2.5yrs | US$165.72k | 0% $ 0 | |
| Independent Director | 1.6yrs | US$555.64k | 0% $ 0 |
3.6yrs
Average Tenure
66.5yo
Average Age
Experienced Board: NRIX's board of directors are considered experienced (3.6 years average tenure).